–News Direct–
Poolbeg Pharma PLC CEO Jeremy Skillington and Tim Cot CEO of Silk Road Therapeutics join Proactive's Stephen Gunnion with details of an exclusive 12-month option agreement with Silk Road Therapeutics for Poolbeg to acquire a novel topical drug aimed at treating oral ulcers in patients with Behet's disease, a rare and debilitating condition.
Skillington said the move is aligned with Poolbeg's strategic focus on rare and orphan diseases.
Cot, with an extensive background in orphan drug approvals from his time at the FDA, highlighted the potential of the drug given its unique formulation and unmet need in the market. He explained the severe impact of Behet's disease, underscoring the innovative potential of their topical treatment in improving the quality of life for those affected.
Both CEO expressed optimism about their collaboration's potential to fast-track this novel treatment to market, leveraging Poolbegs and Silk Road's combined expertise.
Furthermore, Skillington provided insights into Poolbegs financial health and strategic developments over the past year, mentioning a robust cash position of 12.2 million at the end of 2023. He emphasised the company's disciplined capital allocation and the expansion of its intellectual property portfolio.
Looking ahead, Skillington outlined Poolbeg's focus on progressing its pipeline, particularly ongoing projects like POLB001 in the oncology sector, addressing cytokine release syndromea critical side effect in cancer immunotherapies.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/poolbeg-pharma-and-silk-road-therapeutics-announce-strategic-collaboration-on-novel-orphan-drug-620489527
Poolbeg Pharma PLC
COMTEX_451717910/2655/2024-05-01T09:50:31
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Emerald Journal journalist was involved in the writing and production of this article.